FDA approves Xtandi for non-metastatic castration-sensitive prostate cancer with biochemical recurrence

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

On Feb. 2, Nature Medicine published the results of a large, randomized, prospective clinical trial in the nascent and some say, fringe, field of chrono-oncology—the study of how natural biological rhythms might impact cancer outcomes.

FDA halts public release of Complete Response Letters, following citizen petition

FDA will temporarily stop publicly releasing rejection letters as it evaluates potential response to a citizen petition issued by an unnamed pharmaceutical company challenging the legality of the practice.

July 10, 2026

Vol.52 No.27

By Claire Marie Porter

Cancer Policy

FDA proposes rule to hold foreign tobacco companies to U.S. standards

FDA has issued a proposed rule to require both foreign and domestic tobacco manufacturers to register their facilities and list their products with the agency. This closes a regulatory gap, holding overseas e-cigarette and tobacco makers to the same standards as U.S. companies.

July 10, 2026

Vol.52 No.27

By Claire Marie Porter

Clinical Roundup

Should lowest-risk prostate cancer still be called “cancer”? UCLA-led study suggests changing the name could save lives

A growing number of prostate cancer experts argue that calling the lowest-risk prostate cancer “cancer” does more harm than good. A UCLA-led study found removing the cancer label could dramatically reduce overtreatment and encourage more men to get screened, potentially leading to significantly fewer deaths from aggressive prostate cancer.

July 10, 2026

Vol.52 No.27

Cancer Policy

FDA allows ZYN nicotine pouches to make marketing claim: ZYN is safer than cigarettes

FDA is allowing ZYN nicotine pouches, a tobaccoless product that has soared in popularity since in recent years, to make the claim that its products are safer than cigarettes.

FDA approved 17 new cancer treatments in 2025, OCE annual report states

FDA’s Oncology Center of Excellence released its 2025 Annual Report.

July 02, 2026

Vol.52 No.26

FDA approves Xtandi for non-metastatic castration-sensitive prostate cancer with biochemical recurrence

YOU MAY BE INTERESTED IN

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

FDA halts public release of Complete Response Letters, following citizen petition

FDA proposes rule to hold foreign tobacco companies to U.S. standards

Should lowest-risk prostate cancer still be called “cancer”? UCLA-led study suggests changing the name could save lives

FDA allows ZYN nicotine pouches to make marketing claim: ZYN is safer than cigarettes

FDA approved 17 new cancer treatments in 2025, OCE annual report states

Renew today!

Subscriber content

Never miss an issue!

Login

FDA approves Xtandi for non-metastatic castration-sensitive prostate cancer with biochemical recurrence

YOU MAY BE INTERESTED IN

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

FDA halts public release of Complete Response Letters, following citizen petition

FDA proposes rule to hold foreign tobacco companies to U.S. standards

Should lowest-risk prostate cancer still be called “cancer”? UCLA-led study suggests changing the name could save lives

FDA allows ZYN nicotine pouches to make marketing claim: ZYN is safer than cigarettes

FDA approved 17 new cancer treatments in 2025, OCE annual report states

Never miss an issue!

Login

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.